Fabio Patino

Dual-mandate executive role leading convergence of enterprise technology strategy and cybersecurity for global oncology diagnostics leader. Report to CEO, partner with board on digital transformation roadmap, and integrate IT operations, security, cloud infrastructure, and AI innovation into unified business enablement function. Established enterprise governance framework unifying IT strategy, cybersecurity, AI ethics, privacy, and enterprise risk—eliminating traditional silos between technology and security organizations Partner with CEO, COO, and executive team to prioritize and deliver integrated roadmap spanning cloud modernization, AI adoption, security transformation, and platform consolidation. Digital Transformation & AI Integration: Leading AI-enabled transformation initiatives integrating machine learning into diagnostics workflow optimization, predictive analytics for laboratory operations, and intelligent automation for business processes. Architected and executed migration of core enterprise infrastructure to secure cloud environments (AWS/Azure), achieving $5M cost savings while improving scalability by 3x, system resilience to 99.9% uptime, and security posture by 40% Modernizing enterprise application portfolio (ERP, LIMS, QMS) with security-by-design principles embedded from architecture through deployment. Built comprehensive, integrated security program achieving SOC 2 Type II and HIPAA compliance readiness with zero critical findings—enabling enterprise customer expansion and protecting $50M+ deal pipeline Implemented Zero Trust architecture with advanced threat detection, reducing security incident response time by 60% and creating foundation for secure hybrid workforce Deployed enterprise-wide security awareness and culture transformation program, achieving 85% reduction in phishing susceptibility and creating security champions across all business functions

The Sunset Grove focuses on regenerative agriculture to bring you the best coffee in the world while generating a better environment for the future. We go beyond organic!

Dual IT and security leadership for cloud-native proteomics platform company during rapid growth. Unified technology operations, infrastructure, applications, and security into integrated function supporting computational biology innovation. Built from ground up: integrated IT operations and security function serving engineering R&D, commercial operations, and corporate functions with seamless, security-embedded service delivery Delivered SOC 2 Type II and ISO 27001 certifications with zero audit findings in 12 months—critical enabler for $50M+ enterprise customer pipeline requiring compliance validation. Implemented Security by Design framework embedding security architecture, threat modeling, and compliance controls directly into product development lifecycle—eliminating post-development remediation cycles. Designed and deployed secure, scalable AWS multi-account architecture supporting computational biology workloads processing petabytes of proteomics data—enabling 50% faster R&D iteration cycles Architected global cloud infrastructure with data residency controls for GDPR and regional compliance requirements, supporting international expansion strategy. Migrated legacy systems to cloud-native architecture using infrastructure-as-code (Terraform), improving system availability from 95% to 99.9% while reducing infrastructure costs by 30%. Modernized IT service delivery model implementing ITSM best practices, reducing average ticket resolution time by 45% and improving employee satisfaction scores Implemented identity and access management (IAM) framework with SSO and automated provisioning, reducing onboarding time from 3 days to 2 hours Achieved 85% reduction in phishing incidents through comprehensive, role-based security awareness training program with gamification and real-world simulations Established security champions program embedding advocates across engineering, product, and operations—creating security-first mindset without slowing innovation

Unified technology and security leadership for immune medicine company during hypergrowth phase. Integrated IT operations, infrastructure, applications, and security into cohesive function supporting clinical diagnostics platform and immunosequencing research. Implemented unified information security and IT operations program achieving ISO 27001 and SOC 2 Type II compliance in under 12 months—enabling enterprise healthcare system partnerships Integrated DevSecOps practices across engineering organization, embedding security into CI/CD pipelines and shifting security left—reducing vulnerabilities reaching production by 70% Established enterprise risk management framework aligned with NIST Cybersecurity Framework, connecting security investments to business risk tolerance and strategic objectives. Led enterprise cloud modernization initiative across AWS development and production environments supporting clinical diagnostics and immunosequencing platforms Implemented infrastructure-as-code and automated security testing (SAST/DAST/SCA) across development lifecycle, reducing infrastructure deployment time from weeks to hours Reduced infrastructure risk profile while accelerating product development velocity by 25% through modern DevOps practices and platform standardization. Built comprehensive GxP compliance program supporting FDA-regulated clinical diagnostics platform (CLIA lab operations and LDT commercialization). Established data governance framework for PHI/PII management across clinical trial operations, ensuring HIPAA compliance and patient privacy protection. Partnered with legal and privacy teams on GDPR, CCPA, and international data residency strategies supporting global expansion. Modernized enterprise applications including ERP, LIMS, and CRM with integrated security controls and compliance validation. Established technology vendor governance program optimizing $15M software and infrastructure spend

Enterprise technology strategist and operator for global leader in DNA sequencing and genomics through period of dramatic growth ($1.8B to $4.2B revenue). Led comprehensive IT portfolio spanning infrastructure, enterprise applications, security, and digital innovation. Developed and executed 10-year enterprise technology roadmap supporting business strategy spanning M&A integration (7 acquisitions including GRAIL spin-out and reintegration), new product launches, and international expansion Directed $35M annual IT investment portfolio, modernizing core business platforms (SAP ERP, multiple LIMS systems, QMS, Salesforce CRM). Pioneered enterprise robotic process automation (RPA) program, automating 50+ business processes across finance, supply chain, customer service, and quality operations. Scaled IT capability 5x through hybrid delivery model combining strategic outsourcing for commodity services, automation for repetitive tasks, and platform consolidation—while improving service quality metrics. Improved IT operational excellence: 40% reduction in incident resolution time, 50% improvement in change success rate, 99.5% system availability, and 35% increase in employee satisfaction scores. Consolidated and rationalized application portfolio, reducing global SaaS sprawl by 35% while improving user experience and cross-functional data integration. Led IT integration for multiple acquisitions including complex GRAIL transaction (largest healthcare industry transaction at time, $8B valuation). Managed global IT operations across 25+ locations spanning manufacturing facilities, R&D centers, and commercial offices across Americas, Europe, and Asia-Pacific. Implemented identity and access management (IAM) architecture with SSO and automated provisioning across 70+ business applications. Built and led global teams across US, Europe, and Asia-Pacific with 150+ direct and indirect reports spanning IT operations, applications, infrastructure, security, and PMO.

At Illumina, we apply innovative technologies for studying genetic variation and function, making studies possible that were not even imaginable just a few years ago. These revolutionary tools for DNA, RNA, and protein analysis are enabling rapid advances in disease research, drug development, and the development of molecular tests in the clinic. Illumina is the only life sciences company developing genome-wide technologies for genotyping, gene expression and sequencing—the three cornerstones of modern genetic analysis. By enabling studies of thousands of patient samples at once, our products set genetic discovery on fast forward. And we’re just getting started.

Led Fortune 500 digital transformation and cybersecurity programs in life sciences and healthcare. These seven years shaped how I think about technology leadership: strategic problem solving, executive communication, and delivering complex change in regulated environments. Signature Client Engagements Global Pharmaceutical Manufacturer - Digital Transformation ($50M+ Program) Led 3-year transformation across 45 countries for $8B pharmaceutical company. Managed 100+ resources integrating ERP modernization, supply chain optimization, quality system digitization, and cybersecurity. Delivered $25M operational savings through process standardization and platform consolidation. Key innovation: Embedded security into business process redesign from day one, eliminating traditional post-implementation remediation. Medical Device Company - Enterprise Cybersecurity Program Designed comprehensive cybersecurity program achieving FDA 21 CFR Part 11 compliance across manufacturing operations. Conducted enterprise risk assessment, architected secure infrastructure using NIST frameworks, and implemented security operations center with incident response capabilities. Protected company from potential product recalls and FDA enforcement while enabling digital innovation. Healthcare Services Organization - Cloud Strategy Developed cloud strategy and migration roadmap for $2B healthcare company managing patient data across 200+ facilities. Created business case justifying $30M cloud investment with 3-year payback through operational efficiency, improved disaster recovery, and enhanced security posture. Biotech Company - Quality System Modernization Led QMS modernization for biotech preparing for FDA approval of cell therapy product. Redesigned quality processes ensuring GxP compliance while improving efficiency. Result: FDA approval without quality delays and competitive advantage for faster product launches.